PDF
Full
Outline
To evaluate the efficacy and safety of a 12-week regimen of coblopasvir hydrochloride capsules combined with sofosbuvir tablets in patients with chronic hepatitis C (CHC).
CHC patients who visited our hospital and received a 12-week regimen of coblopasvir hydrochloride capsules combined with sofosbuvir tablets were enrolled as the study subjects. All patients received oral coblopasvir hydrochloride capsules (60 mg) and sofosbuvir tablets (400 mg) once daily for 12 weeks. Some patients with genotype 3b additionally received ribavirin tablets for 12 weeks at a dose of 1 000 mg·d-1 for those weighing < 75 kg and 1 200 mg·d-1 for those weighing ≥ 75 kg. Hepatitis C virus (HCV) ribonucleic acid and relevant laboratory indicators were measured before and after treatment. The sustained virological response at 12 weeks post-treatment (SVR12) rate was observed in all patients. Changes in liver and renal function before and after treatment were compared, and safety was evaluated.
A total of 110 CHC patients were enrolled. After treatment, 97.27% (107 cases/110 cases) of patients achieved SVR12. Specifically, the SVR12 rate was 93.33% (14 cases/15 cases) in patients with decompensated cirrhosis, 92.86% (13 cases/14 cases) in patients with genotype 3b CHC, 87.50% (7 cases/8 cases) in patients with moderate-to-severe renal impairment, and 83.33% (5 cases/6 cases) in genotype 3b patients receiving ribavirin combination therapy. The alanine aminotransferase levels before and after treatment were 58.70 (31.85, 100.45) and 20.60 (13.30, 31.33) U·L-1, respectively; the aspartate aminotransferase levels were 52.75 (28.68, 82.13) and 23.30 (17.78, 33.73) U·L-1, respectively; the total bilirubin levels were 13.90 (9.60, 20.25) and 11.70 (8.78, 18.85) μmol·L-1, respectively; the albumin levels were 42.80 (38.10, 45.30) and 45.10 (42.13, 46.73) g·L-1, respectively. After treatment, the aforementioned indicators showed statistically significant differences compared to before treatment (P<0.05, P<0.001). The estimated glomerular filtration rates before and after treatment were 102.09 (87.66, 108.68) and 99.23 (84.00, 104.28) mL·min-1, respectively, with no statistically significant difference (P>0.05). The main adverse drug reactions were fatigue (6.36%), decreased appetite (4.55%), abdominal distension (1.82%) and abdominal pain (1.82%). The overall incidence of adverse drug reactions was 10.91% (12 cases/110 cases), and the incidence in patients with decompensated cirrhosis was 13.33% (2 cases/15 cases). No serious adverse drug reaction occurred.
The 12-week regimen of coblopasvir hydrochloride capsules combined with sofosbuvir tablets demonstrated favorable efficacy and high safety in real-world CHC patients, including those with genotype 3b, decompensated cirrhosis, or moderate-to-severe renal impairment.
PDF
141
25
| 科 Family | 属数 Number of genus | 种数 Number of species | 占总种数比例 Percentage of total species (%) | 属 Genus | 种数 Number of species | 占总种数比例 Percentage of total species (%) |
|---|---|---|---|---|---|---|
| 鹅膏菌科Amanitaceae | 2 | 11 | 5.26 | 鹅膏菌属 Amanita | 10 | 4.78 |
| 小菇科 Mycenaceae | 2 | 12 | 5.74 | 丝盖伞属 Inocybe | 5 | 2.39 |
| 多孔菌科 Polyporaceae | 8 | 14 | 6.70 | 蜡蘑属 Laccaria | 5 | 2.39 |
| 红菇科 Russulaceae | 3 | 23 | 11.00 | 小皮伞属 Marasmius | 6 | 2.87 |
| 小菇属 Mycena | 11 | 5.26 | ||||
| 光柄菇属 Pluteus | 5 | 2.39 | ||||
| 红菇属 Russula | 17 | 8.13 | ||||
| 栓菌属 Trametes | 5 | 2.39 |
关闭全屏
No. 86 Xueyuan South Road, Haidian District, Beijing
010-62199257
qkjq@cast.org.cn
Copyright © 2025 China Association for Science and Technology. All rights reserved. For all open access content, the relevant licensing terms apply.
Sponsored by the Office of the Leading Group for Cybersecurity and Informatization of CAST, and supported by Science and Technology Review Publishing House
